Repare Therapeutics (RPTX)

Company Profile

repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.

Company profile

Ticker

RPTX

Exchange

NASDAQ

Website

reparerx.com

CEO

Lloyd M. Segal

Incorporated

Canada (Federal)

Location

Quebec, Canada

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

SEC CIK

0001808158

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Repare Therapeutics USA Inc. ...

RPTX stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Regulation FD Disclosure

9 Nov 23

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

9 Nov 23

8-K

Regulation FD Disclosure

13 Oct 23

8-K

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial

13 Oct 23

8-K

Regulation FD Disclosure

9 Aug 23

Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

9 Aug 23

8-K

Submission of Matters to a Vote of Security Holders

Latest ownership filings

View all

MARK N LAMPERT

17 Nov 23

SC 13D/A

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND L P

Financial summary

Financial statements Chart RPTX financial data

Quarter (USD)	Sep 23	Jun 23	Mar 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	107.37 mm	107.37 mm	107.37 mm	107.37 mm	107.37 mm	107.37 mm
Cash burn (monthly)	2.73 mm	3.99 mm	12.81 mm	8.75 mm	10.96 mm	10.72 mm
Cash used (since last report)	6.32 mm	9.24 mm	29.69 mm	20.28 mm	25.40 mm	24.85 mm
Cash remaining	101.05 mm	98.13 mm	77.68 mm	87.09 mm	81.97 mm	82.52 mm
Runway (months of cash)	37.1	24.6	6.1	10.0	7.5	7.7

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2023

RPTX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	77	79	-2.5%
Opened positions	8	10	-20.0%
Closed positions	10	7	+42.9%
Increased positions	22	23	-4.3%
Reduced positions	21	23	-8.7%

13F shares	Current	Prev Q	Change
Total value	427.10 bn	368.77 bn	+15.8%
Total shares	48.87 mm	48.44 mm	+0.9%
Total puts	63.70 k	2.10 k	+2933.3%
Total calls	1.06 mm	7.60 k	+13826.3%
Total put/call ratio	0.1	0.3	-78.2%

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	8.29 mm	$0.00	0.0%
BVF	8.29 mm	$100.17 bn	0.0%
Orbimed Advisors	3.32 mm	$40.14 bn	0.0%
Deep Track Capital	3.07 mm	$37.06 bn	+12.5%
CHI Advisors	2.97 mm	$35.84 bn	-1.1%
Versant Venture Management	2.65 mm	$31.97 bn	0.0%
ARK Investment Management	2.62 mm	$31.66 bn	-0.3%
Redmile	2.40 mm	$29.05 bn	-1.0%
MPM Asset Management	2.24 mm	$27.09 bn	0.0%
MPM BioVentures 2014	2.24 mm	$76.41 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Deep Track Capital	3.07 mm	+340.13 k	+12.5%
Logos Global Management	300.00 k	+300.00 k	NEW
Point72 Asset Management	122.30 k	+122.30 k	NEW
Millennium Management	22.69 k	-106.46 k	-82.4%
T. Rowe Price Investment Management	1.80 mm	-106.30 k	-5.6%
Citadel Advisors	118.87 k	-95.76 k	-44.6%
FMR	1.08 mm	-88.56 k	-7.6%
Caption Management	87.09 k	+87.09 k	NEW
Ensign Peak Advisors	344.33 k	+73.43 k	+27.1%
Candriam Luxembourg S.C.A.	0.00	-50.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RPTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Nov 23	Partners L P/il BVF	Common Shares, no par value	Buy	Acquire P	No	No	5.3837	16,143	86.91 k	548,938
16 Nov 23	Partners L P/il BVF	Common Shares, no par value	Buy	Acquire P	No	No	5.3837	125,909	677.86 k	4,308,573
16 Nov 23	Partners L P/il BVF	Common Shares, no par value	Buy	Acquire P	No	No	5.3837	153,693	827.44 k	5,309,432
15 Nov 23	Partners L P/il BVF	Common Shares, no par value	Buy	Acquire P	No	No	4.9999	47,712	238.56 k	532,795
15 Nov 23	Partners L P/il BVF	Common Shares, no par value	Buy	Acquire P	No	No	4.9999	390,507	1.95 mm	4,182,664
15 Nov 23	Partners L P/il BVF	Common Shares, no par value	Buy	Acquire P	No	No	4.9999	493,337	2.47 mm	5,155,739
2 Nov 23	Partners L P/il BVF	Common Shares, no par value	Buy	Acquire P	No	No	3.6	72,479	260.92 k	485,083
2 Nov 23	Partners L P/il BVF	Common Shares, no par value	Buy	Acquire P	No	No	3.6	492,251	1.77 mm	3,792,157
2 Nov 23	Partners L P/il BVF	Common Shares, no par value	Buy	Acquire P	No	No	3.6	218,979	788.32 k	4,662,402
8 Jun 23	Bonita David P	Stock Option Common Shares	Grant	Acquire A	No	No	11.66	27,200	317.15 k	27,200